Track market-moving stories before they get noisy

SummaryAt the end of October, Regeneron Pharmaceuticals, Inc. will report its results for Q3.As a reminder, REGN's Q2 revenue rose 18.8% quarter-on-quarter and 16.6% YoY to $4.29 billion, primarily due to the strong performance of Dupixent.On October 12, Regeneron reported positive Phase 3 OPTIMA results, demonstrating sustained Pasatru efficacy in reducing new HO lesions and disease flare-ups in people with FOP.Meanwhile, REGN trades at just 13.8x forward non-GAAP P/E, versus the sector median of 19.5x.In this article, I'll explain why Regeneron Pharmaceuticals offers an appealing risk/reward profile. Klaus Vedfelt/DigitalVision via Getty Images

Following my August article, "Regeneron: Why I Still See Upside After The Rally," which focused primarily on the anti-PD-1 mAb Opdivo and the blockbuster, called Dupixent, Regeneron Pharmaceuticals, Inc.'s (

3.65K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ALVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The weight-loss market is growing rapidly, and while long-term projections differ on how large it will become, they generally agree that it will maintain its upward trajectory at least over the medium term. Investors can capitalize on this industry's growth by buying shares of those companies likely to emerge as top players. Right now, it looks likely that Eli Lilly (LLY -0.26%) and Novo (NVO -0.71%), the current market leaders, could maintain their lead over the next five years or so. However, other drugmakers are making progress in this field and are worth considering for investors. One of them is Regeneron Pharmaceuticals (REGN -0.26%).

Image source: The Motley Fool.

Regeneron's differentiated approachRegeneron has at least two promising weight loss medicines in its pipeline. One of them is called olatorepatide. Regeneron licensed this medicine from a China-based company. Olatorepatide mimics the actions of the GLP-1 and GIP hormones, placing it in the same broad category as Eli Lilly's market-leading drug, Zepbound.

However, olatorepatide could be particularly attractive for one reason: It appears to display better gastrointestinal (GI) tolerability than competing medicines. In a Phase 3 study conducted in China, olatorepatide led to a mean weight loss of up to 19% over 48 weeks. That's already impressive enough.

But as Regeneron pointed out, olatorepatide also had lower rates of GI-related adverse events -- such as nausea and vomiting -- than what some competing drugs achieved in comparable Phase 3 studies. Regeneron still has to run late-stage clinical trials in the U.S. before it can earn approval in the country.

However, olatorepatide's strong performance in Chinese studies makes it a notable contender in the weight loss market. Regeneron's other leading candidate is trevogrumab. This isn't a drug designed to induce weight loss. Rather, Regeneron is developing trevogrumab to be administered alongside anti-obesity medicines to help patients preserve lean mass as they lose weight.

In a Phase 2 study, trevogrumab, administered alongside Novo's semaglutide, led to lean mass preservation of up to 42.5% compared with just 7.3% in patients receiving semaglutide plus placebo. Trevogrumab is yet another differentiated product that could help Regeneron carve out a niche in the rapidly growing weight loss market.

REGN Regeneron Pharmaceuticals$788.66-$2.09 (-0.26%)

NASDAQ · As of 10:34 AM ET 10/19/26

More reasons to buy the stockOf course, there is much more to Regeneron's business than its weight loss candidates. The company's main growth driver, Dupixent, a medicine for eczema that it co-markets with Sanofi (SNY -1.60%), continues to perform well.

In the second quarter, Regeneron's revenue increased by 17% year over year to $4.3 billion. Dupixent's global sales (recorded by Sanofi) increased 38% year over year to $6 billion. It is helping Regeneron overcome biosimilar competition for Eylea, a medicine approved for several eye-related conditions, including wet age-related macular degeneration.

Regeneron's newer, higher-dose (HD) formulation of Eylea is helping keep the franchise afloat, at least somewhat. Second-quarter combined U.S. revenue from Eylea and Eylea HD declined 12% year over year to $1 billion. But HD Eylea's U.S. sales came in at $596 million, up 52% year over year.

The newer version of the drug comes with fewer injections per year. More convenient dosing can attract new patients while also prompting existing Eylea patients to switch. So, this franchise, despite recent struggles, isn't exactly dead in the water. Regeneron has other products that are contributing to sales growth, particularly Libtayo, a cancer medicine.

And the biotech boasts an attractive pipeline beyond its weight-loss products, including promising anticoagulants being developed to lower the bleeding risk associated with today's anticoagulants. Regeneron has underperformed the broader market over the past two years amid competition for Eylea, but the company is bouncing back, and, given its current approved lineup and pipeline, it could perform well over the medium term. The company's weight loss products may be a key part of the business within five years.

Regeneron Pharmaceuticals (REGN -0.70%) has underperformed broader equities over the past two years. Perhaps the biggest reason for that is the company's declining sales of Eylea, a medicine that treats several eye-related conditions. Regeneron has faced significant competition (biosimilar and otherwise) for Eylea, and despite the company launching a newer formulation of the medicine that is performing well, combined sales of the two versions are still dropping. The good news for Regeneron is that its most important asset continues to perform extremely well.

Image source: The Motley Fool.

Dupixent's rapidly growing sales
Regeneron developed Dupixent in collaboration with Sanofi (SNY +0.79%). The latter records global sales of the medicine and the two companies share U.S. profits equally, while Sanofi gets between 55% and 65% of the profits generated by the drug outside the U.S. Beyond eczema, Dupixent is approved for the treatment of COPD -- an indication it earned in the U.S. just about two years ago -- asthma, and several other conditions. The drug has been posting excellent sales growth and has been instrumental in helping Regeneron overcome its recent challenges.

In the second quarter, Regeneron's revenue grew by a healthy 17% year over year to $4.3 billion. Global sales of Dupixent came in at $6 billion, up 38% year over year. Regeneron's revenue generated from its collaboration with Sanofi grew 51% year over year to $2.2 billion thanks to Dupixent's performance. Regeneron's non-GAAP net income per share jumped 11% year over year to $14.29.

The company's performance was strong, despite lingering Eylea-related headwinds. U.S. sales of the original version of Eylea dropped by 45% year over year to $412 million. The newer, higher dose (HD) formulation performed much better. It posted U.S. revenue of $596 million, up 52% compared to the year-ago period. But combined U.S. revenue from both formulations dropped 12% year over year to about $1 billion. The fact that Regeneron posted a solid quarterly update despite its Eylea-related problems is encouraging.

REGN Regeneron Pharmaceuticals$790.74-$5.60 (-0.70%)

NASDAQ · As of 4:00 PM ET 10/16/26

Where will Regeneron be in five years?
Dupixent is already one of the top-selling drugs in the world, and it should remain so through the end of the decade. Sanofi now expects the medicine to hit 25 billion euros ($27.8 billion) in peak revenue by 2030. So, it should remain a meaningful growth driver. However, the medicine could start facing biosimilar competition in the early 2030s.

Can Regeneron survive that threat? In my view, it can, and here are three reasons why. First, Regeneron and Sanofi plan to defend their Dupixent empire, notably by developing and marketing a different formulation of the medicine that could improve dosing convenience and help it retain many patients beyond the original's patent expiration.

This is the playbook Regeneron followed with Eylea. And while combined sales of Eylea and Eylea HD are declining, that's partly because some patients are switching to the newer, more convenient formulation. Things would be a lot worse for Regeneron had it not earned approval for Eylea HD. Second, Regeneron and Sanofi are collaborating to develop medicines to replace Dupixent.

It's too early to tell whether they will be successful, but it is an encouraging sign for investors. Third, Regeneron has exciting pipeline candidates of its own that could help it navigate a patent cliff for Dupixent down the road. For instance, the company licensed olatorepatide, an investigational weight-loss medicine that mimics the actions of the GLP-1 and GIP hormones, from a China-based biotech.

Olatorepatide appears highly promising. In a Phase 3 study conducted in China, the treatment resulted in a mean weight loss of up to 19% over 48 weeks. Regeneron still needs to conduct clinical trials in the U.S., but olatorepatide could enable the company to capitalize on the rapidly growing weight loss market. Regeneron boasts several other promising candidates as well. Dupixent should remain the company's main growth driver for the foreseeable future, but beyond that, the biotech leader could perform well, provided it makes significant clinical and regulatory progress over the next few years. I'd wager that Regeneron can do so and deliver competitive returns over the medium term.

What happened Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said on October 1, 2026, it entered the Sixth Amendment with Sanofi. Under the amendment, Sanofi will make a $1.0 billion upfront payment.

The companies also agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies that target IL-13, IL-4, IL-4R and IL-4xIL-13. Global profits on sales of the New Licensed Products will be shared equally. Regeneron will be the lead development and lead regulatory party before applications for marketing approval.

Regeneron will remain the lead regulatory party for applications for marketing approval and further commercialization in the United States. Sanofi will be the lead regulatory party for applications for marketing approval and further commercialization outside the United States. Regeneron can also opt in, asset by asset, to Sanofi's Phase 2/3 asset lunsekimig and another early development product after certain trials. If it exercises that option, it will reimburse Sanofi for certain development costs.

In the same filing, Regeneron said it and Sanofi entered a settlement agreement. Under it, Regeneron agreed to dismiss its lawsuit over information access and audit rights.

Key numbers Metric Latest Change Source Upfront payment $1.0 billion SEC 8-K Potential milestone payments up to an additional $7.0 billion SEC 8-K New long-acting antibodies 4 antibodies SEC 8-K Expected acquired IPR&D charge $22 million SEC 8-K Expected net income per diluted share impact -$0.18 SEC 8-K Read more: Regeneron Pharmaceuticals (REGN) stock analysis and investment case

Why it matters OptimistFi's case is that Regeneron turns a concentrated set of approved biologics into durable free cash flow that funds research and development, buybacks and pipeline investment. This agreement is mixed for that case.

The $1.0 billion upfront payment is about 45 times the approximately $22 million pre-tax acquired in-process research and development charge Regeneron expects in third quarter 2026. That gives Regeneron immediate cash and shared economics if the antibodies succeed. But the filing says up to an additional $7.0 billion depends on development, regulatory and commercial milestones.

It also says development costs above a budget cap fall to Regeneron, subject to later recoupment. The separate settlement also means Regeneron agreed to dismiss a lawsuit tied to Dupixent information access and audit rights.

Browse: stock research on every company OptimistFi covers

What's next Regeneron said the full Sixth Amendment will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026. That filing will also include Regeneron's final third-quarter 2026 results, which are still subject to closing procedures.

A filing that confirms the $1.0 billion payment and the expected charge would support the cash-flow case. Slippage on either would weaken it.

More from OptimistFi REGN stock: the Regeneron Pharmaceuticals thesis, its status and the next test to watch United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze Meta Platforms, Inc. (NASDAQ: META) Has a Conditional $18 Billion Bill Stock research on every company OptimistFi covers Latest stock research and investment-case updates OptimistFi: evidence-first equity research Sources SEC 8-K — Current report on Form 8-K covering the Sixth Amendment, settlement and third-quarter charge estimate. Read the full OptimistFi thesis on Regeneron Pharmaceuticals, Inc.: https://optimistfi.com/stocks/REGN

See what would break the Regeneron Pharmaceuticals, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

The full Regeneron Pharmaceuticals, Inc. investment case, its status and the next test to watch live on the Regeneron Pharmaceuticals, Inc. thesis page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.

LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy

Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free survival in 11 patients with recurrent and heavily pre-treated LGSOC treated with the highest dose of ubamatamab in the trial  

Regeneron has been enrolling a dedicated LGSOC cohort at this dose and will advance ubamatamab into a confirmatory Phase 3 trial of this lethal cancer with limited treatment options

TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first results for the investigational ubamatamab in patients with low-grade serous ovarian cancer (LGSOC). The data are from an ongoing Phase 1/2 trial in recurrent platinum-resistant high- or low-grade serous ovarian cancer that were presented in a late-breaking plenary oral session at the International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting. Ubamatamab is a MUC16xCD3 bispecific antibody designed to bridge MUC16 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation. Based on these preliminary trial results, Regeneron has been enrolling a single-arm, potentially registrational LGSOC trial and will be discussing the data with the U.S. Food and Drug Administration (FDA) in the coming months. Regeneron is also planning to initiate a confirmatory, randomized, controlled Phase 3 trial to support the use of ubamatamab in LGSOC.

LGSOC is a biologically distinct variant from the more common high-grade serous ovarian cancer (HGSOC), comprising up to 10% of serous ovarian cancer, with typically uniformly high MUC16 expression and limited treatment options. The disease often affects younger women and is characterized by slower-growing tumors than those seen in HGSOC, but frequently recurs and is less responsive to conventional chemotherapy with few treatment options. LGSOC has a median overall survival of approximately seven years from initial diagnosis, compared to approximately four years for HGSOC. In recurrent advanced LGSOC, historical trial data have shown that objective response rates (ORRs) generally remain below 15% with chemotherapy and endocrine therapy, while the only approved therapy has an ORR of 44% in biomarker-selected patient populations (representing about 30% of the overall LGSOC population).

“The high rate of durable responses observed thus far with ubamatamab in low-grade serous ovarian cancer, without requiring biomarker selection, are highly encouraging and reinforce our excitement about MUC16 as a new therapeutic target in this difficult-to-treat disease,” said Israel Lowy, M.D., Ph.D., Clinical Development Unit Head, Oncology, at Regeneron. “This initial clinical evidence highlights the potential of our bispecific approach to bring a differentiated and first-in-class treatment option to patients in need. We are pleased with the safety profile of the drug as well, and are eager to build on these findings through our ongoing trial and planned confirmatory Phase 3 trial.”

Data presented at IGCS focused on the LGSOC subset of 19 patients who had received a median of four prior lines of therapy and were dosed with intravenous ubamatamab ranging from 3 to 800 mg weekly or every three weeks. Ubamatamab was given either as monotherapy or in combination with Libtayo® (cemiplimab).

Included in the presentation were 11 patients treated with 800 mg of ubamatamab monotherapy, eight treated weekly and three treated every three weeks. Results at the 800 mg doses showed a:

73% ORR (95% Confidence Interval [CI]: 39.0 to 94.0), with all responses being partial responses9-month median duration of response (95% CI: 6.9 to not estimable [NE]), per Kaplan-Meier estimate11-month median progression-free survival (95% CI: 3.0 to NE), per Kaplan-Meier estimate Safety was assessed across all 19 patients in the LGSOC subset. Treatment-emergent adverse events (TEAEs) occurred in 100% of participants (n=19). Cytokine release syndrome occurred in 90% of participants (n=17), all of which were Grade 1 or 2. Serious TEAEs grade 3 or higher occurred in 21% (n=4) of participants and treatment-related adverse events (TRAEs) occurred in 74% of participants (n=14). Grade 3 or higher TRAEs included neutropenia (21%; n=4), anemia (11%; n=2), increased alanine aminotransferase (11%; n=2), increased aspartate aminotransferase (11%; n=2), abdominal pain (5%; n=1) and ileus (5%; n=1). Most adverse events occurred during the step-up dosing period. One participant discontinued treatment due to a stroke considered unrelated to ubamatamab treatment; no TEAEs resulted in death.

The potential uses of ubamatamab described above are investigational, and its safety and efficacy have not been evaluated by any regulatory authority.

About the Trial
The ongoing, open-label, Phase 1/2 trial is evaluating ubamatamab alone and in combination with Libtayo in adult patients with recurrent platinum-resistant ovarian cancer and other recurrent MUC16-expressing cancers.

The Phase 1 portion of the trial is primarily assessing safety, tolerability, dose-limiting toxicities and pharmacokinetics of ubamatamab, with efficacy evaluated as a secondary endpoint through measures such as ORR, duration of response and progression-free survival. The Phase 2 portion is evaluating the anti-tumor activity of ubamatamab, primarily through ORR, while continuing to assess safety and tolerability.

A prospective, dedicated, potentially registrational cohort in the Phase 2 portion of this trial is evaluating ubamatamab 800 mg monotherapy every three weeks in up to 100 patients with recurrent LGSOC and is currently enrolling. If you are interested in learning more about this trial, please contact us ([email protected], +1 844 734 6643), or visit our clinical trial website.

About Ovarian Cancer
Ovarian cancer is one of the most common gynecologic cancers and remains a leading cause of cancer-related mortality among women. It arises from the uncontrolled growth of abnormal cells in the ovary and is frequently diagnosed at an advanced stage, when disease has spread beyond the ovary. In 2026, an estimated 21,010 new cases of ovarian cancer were expected to be diagnosed in the U.S., and approximately 12,450 women were expected to die from the disease. Despite advances in treatment, ovarian cancer remains a significant unmet medical need, with many patients ultimately experiencing disease recurrence and progression. 

LGSOC is a distinct form of ovarian cancer that occurs in younger women and comprises up to 10% of new epithelial ovarian cancer cases. While LGSOC tumor cells tend to grow and divide more slowly than those seen in high-grade serous ovarian cancer, the disease frequently recurs and is less responsive to conventional chemotherapy. LGSOC has a median overall survival of approximately seven years from initial diagnosis, compared to approximately four years for HGSOC. Although endocrine therapy and targeted therapies are used in selected patients, treatment options remain limited for many people with recurrent disease.

About Regeneron in Cancer
We aspire to turn revolutionary discoveries into medicines that can transform the lives of those impacted by cancer. Our team around the world is driven to solve the needs and challenges of those affected by one of the most serious diseases of our time.

Backed by our legacy of scientific innovation and a deep understanding of biology, genetics and the immune system, we’re pursuing potential therapies across more than 30 types of solid tumors and blood cancers. Our cancer strategy is powered by cutting-edge technologies and therapies that can be flexibly combined to investigate potentially transformative treatments for patients. Oncology assets in clinical development comprise nearly half of Regeneron’s pipeline, and include checkpoint inhibitors, bispecific antibodies and costimulatory bispecific antibodies. Our approved PD-1 inhibitor Libtayo serves as the backbone of many of our investigational combinations. To complement our extensive in-house capabilities, we collaborate with patients, healthcare providers, governments, biopharma companies and each other to further our shared goals. Together, we are united in the mission to serve as a beacon of transformation in cancer care.

About Libtayo    
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC), advanced NSCLC and advanced cervical cancer.  

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. FDA. Outside of the U.S., the generic name of Libtayo in its approved indications is cemiplimab.   

The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either conventional or novel therapeutic approaches for other solid tumors. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.     

What is the most important information I should know about LIBTAYO?  
LIBTAYO is a medicine that may treat certain cancers by working with your immune system. LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended. 

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:  

Lung problems: cough, shortness of breath, or chest pain   Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, or severe stomach-area (abdomen) pain or tenderness   Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach-area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than normal   Hormone gland problems: headache that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, or changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness   Kidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, or loss of appetite   Skin problems: rash, itching, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat, or genital area, fever or flu-like symptoms, or swollen lymph nodes   Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LIBTAYO. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles, confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs, double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight, persistent or severe muscle pain or weakness, muscle cramps, low red blood cells, or bruising   Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: nausea, vomiting, chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain, or facial swelling   Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ or tissue transplant that you have had   Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LIBTAYO. Your healthcare provider will monitor you for these complications   Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with LIBTAYO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects. 

  Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you:

have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus   have received an organ or tissue transplant, including corneal transplant    have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)   have received radiation treatment to your chest area   have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome   are pregnant or plan to become pregnant. LIBTAYO can harm your unborn baby   Females who are able to become pregnant:  

Your healthcare provider will give you a pregnancy test before you start treatment   You should use an effective method of birth control during your treatment and for at least 4 months after your last dose of LIBTAYO. Talk to your healthcare provider about birth control methods that you can use during this time   Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LIBTAYO   are breastfeeding or plan to breastfeed. It is not known if LIBTAYO passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of LIBTAYO    Tell your healthcare provider about all the medicines you take, including prescription and over- the-counter medicines, vitamins, and herbal supplements. 

  The most common side effects of LIBTAYO when used alone to treat CSCC that has spread or cannot be cured by surgery or radiation, BCC, or NSCLC include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia). The most common side effects of LIBTAYO when used alone to help prevent CSCC from coming back include rash and itching. The most common side effects of LIBTAYO when used in combination with platinum-containing chemotherapy to treat NSCLC include hair loss, muscle or bone pain, nausea, tiredness, numbness, pain, tingling, or burning in your hands or feet, and decreased appetite. 

  These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296. 

  Please see full Prescribing Information, including Medication Guide.

About Regeneron's VelocImmune® Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara®, Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn), Veopoz® (pozelimab-bbfg) and Pasatru™ (garetosmab-grts). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. A total of 11 antibody and bispecific products have been approved or authorized worldwide that were invented or derived using VelocImmune technologies.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation ubamatamab (MUC16xCD3 bispecific antibody), Libtayo® (cemiplimab), and the other clinical programs discussed or referenced in this press release; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as ubamatamab as a monotherapy or in combination with Libtayo® (cemiplimab) for the treatment of low-grade serous ovarian cancer; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as ubamatamab); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as ubamatamab) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Contacts:

Media Relations 
Taylor Ramsey Skott
Tel: +1 914-409-2381
[email protected] Relations
Mark Hudson
Tel: +1 914-847-3482
[email protected]

An experimental weight-loss drug being developed by Regeneron (REGN.O) used in combination with Novo Nordisk's (NOVOb.CO) semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone ​in a study of patients with obesity, according to data being presented at a medical meeting.

With the explosive popularity ‌of GLP-1 weight-loss drugs such as Novo's semaglutide, sold as Wegovy for obesity, there has been growing concern about significant loss of muscle accompanying rapidly shed pounds.

The Regeneron drug, trevogrumab, belongs to a different class of medicines that inhibits the protein myostatin, which is linked to loss of muscle mass.

When researchers ​measured thigh muscle in patients with MRI scans, the addition of a 75-milligram dose of trevogrumab preserved over 70% of ​muscle mass loss compared with semaglutide alone at 52 weeks, a summary of the data showed.

"We ⁠confirmed that indeed patients that take GLP-1s lose about 30% of their weight in the form of lean muscle mass, that with ​trevogrumab we can prevent," said Regeneron executive Boaz Hirshberg, adding the greatest benefit could potentially be for patients who begin treatment with ​lower muscle mass.

Data from the trial of nearly 1,000 patients between the ages of 18 and 65 was being presented at the European Association for the Study of Diabetes conference in Milan on Thursday.

Wall Street and the medical community are looking for evidence that next-generation drugs like anti-myostatins can prevent the ​body from breaking down muscle during weight loss.

At least a dozen companies are working on muscle-preserving therapies, with analysts forecasting the medicines could reach $30 ​billion in annual sales by 2035.

The multi-pronged trial initially included a second experimental Regeneron antibody drug, garetosmab.

In the first 26 weeks, two participants who received higher ‌doses of ⁠trevogrumab in combination with garetosmab died. One death was due to an undetermined cause in a patient with multiple cardiovascular risk factors and the second was caused by cardiac arrest in a person with a history of cardiovascular disease, the company said.

Trevogrumab alone showed a safety profile similar to semaglutide, with no unexpected side effects, the company said.

The trevogrumab/garetosmab combination led to greater lean-mass preservation than trevogrumab ​alone but had a high ​rate of adverse side effects, ⁠including muscle spasms. Regeneron said it will not move forward with the triple combination.

The mid-stage study was performed as a two-part trial.

In one part of the trial, patients on semaglutide alone lost 6.7% of ​their lean muscle mass over 26 weeks. Those who also took 75 milligrams of trevogrumab lost ​only 3.3% of ⁠muscle mass. The combination with 25 mg of trevogrumab led to 4.7% loss of muscle mass.

When patients stopped semaglutide but kept taking trevogrumab, their muscle mass returned to where it started before the study, suggesting the drug could help rebuild the lost muscle, the company said.

Regeneron said ⁠it has ​selected the 75-mg once-weekly dose for further studies and plans another mid-stage trial ​in patients over 65.

"What we want to do is concentrate on the quality of weight reduction," Regeneron's Hirshberg said. "We want to find the best way to approach ​weight reduction, especially in vulnerable patients."

Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) stock is trading lower on Monday, probably in reaction to positive data from Kodiak Sciences Inc.’s (NASDAQ:KOD) data from the Phase 3 DAYBREAK trial for wet age-related macular degeneration (wAMD).

The study demonstrated that Zenkuda and tabirafusp-ted provided non-inferior vision gains compared to Regeneron’s Eylea (aflibercept) after one year.

Zenkuda showed a strong, immediate clinical effect during the initial treatment phase, comparable to or exceeding aflibercept.

FDA Regulatory Context And Eylea HD ApprovalsIn November 2025, the U.S. Food and Drug Administration (FDA) approved Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing period.

The FDA also approved a monthly dosing option for some patients who may benefit from resuming this dosing schedule across approved indications: wAMD, diabetic macular edema (DME), diabetic retinopathy (DR), and RVO.

Kodiak Focuses On Six-Month Dosing BenchmarkInvestors should note that Kodiak Sciences is assessing a six-month dosing schedule.

Kodiak noted that the six-month dosing establishes a first-line benchmark in wAMD.

“Twenty years after Lucentis (ranibizumab) was approved for wet AMD, the holy grail remains the same: robust anatomic disease control and maximal visual gains, sustained with less frequent dosing,” said David Brown, Chief Medical Officer, Retina Consultants of America.

Read Next

“The DAYBREAK results with Zenkuda are truly impressive. Under an AI-guided retreatment algorithm that closely mirrors the zero-fluid-tolerance approach we use in clinic, more than half of patients were maintained on 24-week dosing through year one,” Brown further commented.

Latest Financial Performance of EyleaNet product sales of Eylea HD increased 52% to $596 million in the second quarter of 2026, primarily due to higher sales volumes driven by increased demand, partly offset by a lower net selling price.

Net product sales of Eylea fell 45% to $412 million, negatively impacted by lower sales volumes driven by decreased demand as a result of continued competitive pressures and the continued transition of patients to EYLEA HD, and a lower net selling price.

REGN Price Action: Regeneron Pharmaceuticals shares were down 3.45% to $760.83 at the time of publication on Monday, according to Benzinga Pro data.

Read Next

Photo: Shutterstock

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Regeneron Pharmaceuticals' (REGN +1.07%) shares climbed well above $1,000 two years ago, reaching all-time highs. However, they have dropped significantly from those levels over the past 24 months and now sit slightly below $800 apiece. What has happened to Regeneron? Is the stock a great buy at current levels? Let's find out.

Recent financial results In the second quarter, Regeneron's revenue increased by 17% year over year to $4.3 billion. That was a strong performance for the biotech, largely driven by its biggest growth driver, Dupixent, a medicine it co-markets with Sanofi (SNY +0.13%). Dupixent's global net sales (recorded by Sanofi) jumped 38% year over year to $6 billion.

Image source: The Motley Fool.

Dupixent is one of the leading medicines in the eczema market, but newer indications, including in COPD, are contributing as well. Dupixent should remain Regeneron's most important growth driver until the early 2030s, when it could potentially lose patent exclusivity. However, Regeneron and Sanofi have a plan to defend their empire, notably by developing a newer, higher-dose (HD) formulation of Dupixent that could earn approval in some of Dupixent's existing indications and retain many of its patients.

Can this strategy work? It's worth noting that Regeneron took the same approach with its other growth driver, Eylea, which treats several eye-related disorders. Eylea started facing biosimilar competition in late 2024. Even before that, it faced a more competitive landscape, especially since Roche's (OTC: RHHBY) Vabysmo was approved in January 2022. But the launch of HD Eylea, which earned approval in 2023, is helping mitigate the losses from the original version.

In the second quarter, combined U.S. sales of Eylea and Eylea HD were about $1 billion, down 12% year over year. U.S. revenue from Eylea HD came in at $596 million, up 52% year over year, while sales of the original version in the country declined 45% year over year. Eylea HD will likely continue to gain traction, thanks to its friendlier dosing schedule. And as the impact of declining Eylea sales on Regeneron's financial results weakens, the company could maintain robust top-line growth.

Premium Feature

Moneyball Superscore

76/100

Today's Change

(

1.07

%) $

8.52

Current Price

$

806.69

New products could contribute, too Eventually, Regeneron will have to develop new blockbuster products. The company has several interesting candidates, including an investigational weight loss medicine called olatorepatide. This therapy mimics the actions of the gut hormones GLP-1 and GIP, just like the current market leader, Zepbound. That doesn't guarantee approval, not by a long shot, but there is another important fact to know: Regeneron licensed olatorepatide from a China-based biotech, and the anti-obesity treatment has already posted strong phase 3 study results in China. In a late-stage trial enrolling 604 patients, the medicine led to a weight loss of up to 19% over 48 weeks. Zepbound recorded an average weight loss of 20.2% in one 72-week clinical trial.

Does that mean olatorepatide is the superior medicine? Not necessarily. There are several caveats to keep in mind, including the difficulty of comparing across clinical trials and the fact that the olatorepatide study was in China. Still, the medicine looks highly promising and could become a notable player in the already large and fast-growing weight-loss market. Of note, Regeneron is also developing a medicine that could be administered alongside GLP-1s to help patients maintain muscle mass as they lose weight.

And beyond this promising therapeutic area, Regeneron is working on products in other fields, including oncology, immunology, and more.

The company could have a much stronger lineup of approved drugs by the end of the decade.

Regeneron's shares have lagged broader equities over the past two years, largely due to its Eylea-related problems. But the company's financial results have improved significantly in recent quarters; Eylea HD continues to gain steam; it has a long-term plan to keep its Dupixent empire mostly intact; and it is developing several promising pipeline candidates, such as olatorepatide. Even with the very real possibility of clinical and regulatory setbacks, my view is that Regeneron's shares look very attractive at current levels -- with its shares trading below $800 apiece -- especially once we factor in its dividend and share buyback programs.

Amylyx Stock: Why the Full Pipeline Story MattersRegeneron Pharmaceuticals NASDAQ: REGN executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance.

Ryan Crowe, senior vice president of investor relations and strategic analysis, said the company’s second-quarter financial performance featured double-digit top- and bottom-line growth, supported by commercial execution across EYLEA HD, DUPIXENT and LIBTAYO. He said each of those products reached all-time quarterly sales highs during the period.

Get REGN alerts:

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them AllCrowe also said Regeneron had completed repayment of its Sanofi development balance at the end of the second quarter. As a result, the company will record its full share of profits from DUPIXENT and KEVZARA within Sanofi collaboration revenue going forward.

Pipeline catalysts expected through 2026 The company highlighted several anticipated milestones for the remainder of 2026, including a November PDUFA date for cemdisiran monotherapy in generalized myasthenia gravis. Crowe described the condition as a large and growing market and said Regeneron believes its product could be differentiated. The company is also expecting pivotal data in paroxysmal nocturnal hemoglobinuria for pozelimab plus cemdisiran versus eculizumab, marketed as SOLIRIS.

Pfizer Adds to Its Big Bet on Weight Loss DrugsIn geographic atrophy, Regeneron expects an interim readout evaluating pozelimab plus cemdisiran and cemdisiran monotherapy. Crowe said the data could help determine next steps for the program, including pivotal-trial powering and whether fewer treatment arms may be needed.

Other expected developments include early data from metabolic programs in MASH and postural orthostatic tachycardia syndrome, or POTS, as well as the initiation of pivotal studies for olatorepatide in obesity and type 2 diabetes. Regeneron in-licensed olatorepatide from Hansoh in 2025 and holds global rights outside China.

Crowe said the company sees additional opportunity in its C5 franchise, its BCMA bispecific linvoseltamab, Factor XI anticoagulation programs and its genetics database. He said Regeneron has spent 12 years building a genetics database linked to electronic health records and is adding proteomics data to support target discovery and disease management.

EYLEA HD gains momentum as prefilled syringe decision nears Marion McCourt, executive vice president and head of commercial, said EYLEA HD’s performance benefited from label enhancements that included every-four-week dosing, the retinal vein occlusion indication and durability data supporting dosing intervals of up to 20 weeks.

McCourt said physician experience with EYLEA HD has been positive, with physicians viewing the product as having strong durability across indications. She said retinal vein occlusion represents about 20% of the market and that the company has seen substantial switching from EYLEA to EYLEA HD in that segment. She added that EYLEA HD is receiving more switches than other products across the anti-VEGF category, while also gaining treatment-naive patients.

According to McCourt, EYLEA HD represented 60% of Regeneron’s total EYLEA franchise sales in the second quarter, up from about 50% in the preceding quarter. She said EYLEA HD was the fastest-growing innovative branded product in its category.

Regeneron continues to target approval of an EYLEA HD prefilled syringe by year-end. Crowe said the company is working with multiple contract manufacturers to address FDA-identified facility issues, rather than issues involving the product itself. He said approval remains possible by the end of the year at one or more manufacturing organizations.

Executives acknowledged expected competition from additional biosimilars to EYLEA 2 mg but emphasized that EYLEA HD’s durability profile differentiates it from the 2 mg aflibercept segment. Crowe said patients who move to biosimilar aflibercept could remain potential candidates for EYLEA HD over time.

DUPIXENT growth and Sanofi collaboration McCourt said DUPIXENT has reached a $24 billion annualized revenue run rate and remains underpenetrated across its indications. She said atopic dermatitis represents roughly half of the product’s patient population, while other growth opportunities include biologic asthma, COPD, eosinophilic esophagitis, chronic spontaneous urticaria, chronic rhinosinusitis and bullous pemphigoid.

McCourt said DUPIXENT’s safety profile, use across multiple type 2 inflammatory diseases and applicability among patients with comorbidities remain key differentiators. She said more than 1.5 million patients have been treated with the drug.

On competition from longer-acting therapies, McCourt said Regeneron is preparing commercial and medical teams to discuss competing products but believes DUPIXENT benefits from its established safety record, payer coverage, ease of use and patient experience. She added that new entrants can also raise awareness and encourage patients to seek treatment.

Regeneron is also discussing a potential expansion of its collaboration with Sanofi beyond DUPIXENT. Crowe said the companies are approaching discussions with “open minds, mutual respect, and a reset of the relationship,” though he said it was too early to predict timing or terms.

The company is advancing several long-acting antibodies targeting the IL-4/IL-13 pathway. Crowe said a Regeneron-owned long-acting IL-13 antibody is being tested in healthy volunteers and could potentially enter Phase III as early as late 2027 or early 2028. He said advancing a long-acting IL-4 receptor alpha program into the clinic would require discussion with Sanofi because that receptor is covered by the existing collaboration.

Commercial preparation for new markets McCourt said Regeneron is building a neurology business unit ahead of a potential cemdisiran launch in generalized myasthenia gravis. She said the company has added internal and external talent with neurology experience and expects its field organization to be launch-ready ahead of the November PDUFA date.

In obesity, Crowe said Regeneron is developing olatorepatide as a potential backbone therapy and is pursuing a co-formulation with PRALUENT. The company is running a study of weekly PRALUENT dosing, which would be needed for co-administration with the weekly obesity therapy. Crowe said Regeneron believes it will need to offer more than marginal weight-loss differences to compete, pointing to potential gastrointestinal tolerability benefits and LDL reduction as possible sources of differentiation.

Finally, Crowe said Regeneron remains active in evaluating business-development opportunities but will maintain its discipline on price. Internal investment remains the company’s capital-allocation priority, he said, while its balance sheet provides flexibility to pursue deals that can benefit from Regeneron’s development, commercialization, genetics and manufacturing capabilities.

About Regeneron Pharmaceuticals (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

AlphaGrep UK Ltd acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,943 shares of the biopharmaceutical company’s stock, valued at approximately $1,212,000. Regeneron Pharmaceuticals comprises 0.4% of AlphaGrep UK Ltd’s portfolio, making the stock its 22nd largest holding.

A number of other institutional investors also recently made changes to their positions in the company. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $26,000. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $26,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $29,000. Trust Co. of Vermont bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $29,000. Institutional investors own 83.31% of the company’s stock.

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Recent commentary continues to view Regeneron as a potentially attractive long-term biotech investment, supported by its established commercial portfolio, development pipeline and strong financial profile. However, the comparison with Vertex reportedly gives Vertex the clearer near-term investment edge. Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? Neutral Sentiment: Regeneron’s Phase 1/2 study combining cemiplimab with SNS-101 has been completed, providing a pipeline milestone, although no efficacy or regulatory results were released. Cemiplimab Combination Trial Completion Negative Sentiment: Several law firms are recruiting investors for a securities class action alleging that Regeneron and certain executives misled shareholders about the viability and risks of the Phase 3 Fianlimab-Libtayo trial, including its protocol change and failure to meet the primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates potential reputational, legal and financial risks. Regeneron Class Action Deadline Alert Negative Sentiment: Director Kathryn Guarini sold 400 shares for $340,000, while EVP Marion McCourt sold 2,346 shares for approximately $2.0 million. All sales were made under pre-arranged Rule 10b5-1 plans, reducing their value as discretionary bearish signals, but the transactions may weigh on sentiment near recent highs. SEC Insider Transaction Filing Insider Buying and Selling at Regeneron Pharmaceuticals In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the transaction, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur Ryan sold 200 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 4,146 shares of company stock valued at $3,432,488. 6.97% of the stock is owned by insiders. Analysts Set New Price Targets REGN has been the subject of a number of recent research reports. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. HSBC dropped their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Finally, BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Fourteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $800.36.

View Our Latest Stock Analysis on REGN

Regeneron Pharmaceuticals Trading Down 1.9% NASDAQ REGN opened at $827.72 on Friday. The company has a market cap of $85.22 billion, a price-to-earnings ratio of 20.46, a price-to-earnings-growth ratio of 1.65 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $859.34. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The business’s fifty day moving average is $738.29 and its 200 day moving average is $720.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $12.81 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

About Regeneron Pharmaceuticals (Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

See Also Five stocks we like better than Regeneron Pharmaceuticals Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Bank of New York Mellon Corp bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 758,492 shares of the biopharmaceutical company’s stock, valued at approximately $472,950,000. Bank of New York Mellon Corp owned approximately 0.72% of Regeneron Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the company. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $1,350,000. State of Wyoming purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $74,000. ABN AMRO Bank N.V. purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $422,000. GSA Capital Partners LLP acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $509,000. Finally, Stoneridge Investment Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $657,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert Insider Activity at Regeneron Pharmaceuticals In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,400 shares of company stock valued at $1,090,030. Insiders own 6.97% of the company’s stock. Analysts Set New Price Targets A number of brokerages recently weighed in on REGN. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research note on Tuesday, July 7th. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Wells Fargo & Company increased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Finally, Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Sixteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $801.70.

Read Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Up 0.9% REGN stock opened at $834.04 on Friday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $697.09 and its 200 day moving average price is $716.73. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $847.00. The company has a market cap of $85.87 billion, a P/E ratio of 20.61, a P/E/G ratio of 1.41 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period last year, the business posted $12.81 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Further Reading Five stocks we like better than Regeneron Pharmaceuticals Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability 

Approval based on results from the OPTIMA trial demonstrating a 90% or greater reduction in new HO lesions at 56 weeks with a dramatic reduction in clinician-assessed flare-ups in adults with FOP

TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Recognizing the significant mobility challenges faced by many people with FOP, Pasatru can be administered across a range of care settings, including home infusion where appropriate. The recommended starting dosage is based on weight at 10 mg/kg and is given intravenously over 60 minutes once monthly (every four weeks) but may be decreased to a 3 mg/kg infusion over 60 minutes once monthly if not tolerated. Pasatru is a VelocImmune®-derived, fully human monoclonal antibody that blocks Activin A, a protein that Regeneron scientists discovered to be critical in the development of HO lesions in people with FOP.

FOP is an ultra-rare genetic disorder in which muscles, tendons, ligaments and other connective tissues are progressively infiltrated by rogue bone formation, a process known as HO. HO of the jaw, spine, hip and rib cage can make basic actions such as speaking, eating, walking or breathing difficult, and the dysfunction of these structures can lead to escalating loss of mobility. Worldwide, approximately 900 people are diagnosed with FOP, and most patients are wheelchair-bound by age 30 with the median age of survival being 56.

“For people living with FOP, every irregular new bone formation is a step toward disability and potential loss of mobility,” said Dr. Kathryn Dahir, Professor in the Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism at Vanderbilt University, and a primary investigator for the OPTIMA trial. “With the ability to reduce the number of new bone lesions and flare-ups, we now have a new treatment that can positively affect patients.”

“FOP is a relentless, restrictive condition that severely impacts the lives of those diagnosed and their families,” said Michelle Davis, Executive Director of the International FOP Association. “This approval is monumental for our community, providing a vital new therapy that can have a significant impact on the life of someone with FOP."

Pasatru was granted approval based on efficacy and safety data from the positive Phase 3 OPTIMA trial evaluating Pasatru in adults with FOP. At 56 weeks, both doses of Pasatru, 10 mg/kg (n=23) and 3 mg/kg (n=19), met the primary endpoint and were highly efficacious in reducing the total number of new HO lesions as compared to placebo (n=21), demonstrating a 90% (2 lesions vs. 19 lesions) and 94% (1 lesion vs. 19 lesions) reduction, respectively, as assessed by computed tomography (CT) scan. The number of clinician-assessed flare-ups during this time, a key secondary endpoint, were 9 for Pasatru 10 mg/kg (88% reduction compared to placebo), 53 for Pasatru 3 mg/kg (15% reduction compared to placebo), and 66 for placebo. Changes in the proportion of patients with patient-reported flare-ups through week 56 were not significantly different between placebo and Pasatru treatment groups. At 56 weeks, among all 63 people who participated in the trial, serious treatment-emergent adverse events occurred in 2 patients treated with 10 mg/kg Pasatru, 1 patient treated with 3 mg/kg Pasatru, and 2 patients treated with placebo. The most common adverse reactions occurring in ≥10% of adults with FOP treated with Pasatru 10 mg/kg or 3 mg/kg were abscess, acne, increased hair growth, madarosis (loss of eyebrows), oral ulcers, epistaxis (nosebleeds), folliculitis, paronychia (nail infection), and rash.

“The approval of Pasatru is the culmination of decades of pioneering research that Regeneron has pursued alongside the FOP community, rooted in our discovery of the role that Activin A plays in driving this disease,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. “People living with FOP have needed a new treatment option for this devastating condition far too long, much like many others living with a rare disease. This unprecedented milestone embodies our broader mission to continue delivering new options for those who have long faced limited treatment options and our relentless commitment to bringing scientific breakthroughs to families, no matter the prevalence of the condition they manage.”

Regeneron is committed to supporting people living with rare diseases. Regeneron’s myRARE™ program offers resources to help patients and healthcare providers, including product information, insurance benefit verification, and information about potential financial support. To learn about myRARE, visit myRARE.com or call 1-833-4my-RARE (1-833-469-7273).

In the European Union, a regulatory submission for Pasatru is currently under review by the European Medicines Agency. Additional regulatory submissions are planned in countries around the world, including Japan. Pasatru previously received Fast Track designation and Orphan Drug Designation from the FDA, as well as Orphan Designation by the European Medicines Agency in the European Union and the Ministry of Health, Labour and Welfare in Japan.

About the OPTIMA Clinical Trial 
OPTIMA is a Phase 3, multi-center, multinational trial to assess the efficacy of Pasatru on the reduction of heterotopic bone formation and flares, as well as its safety, tolerability, and pharmacokinetics, in patients with active FOP. 

The trial enrolled 63 participants aged 18 years and older who have any FOP-causing variant of type I Activin A receptor (ACVR1), exhibited FOP disease activity or progression of HO lesions, and had a cumulative analogue joint involvement scale (CAJIS) score at screening of ≤19. CAJIS is a scoring tool used by clinicians to assess the degree of joint involvement, with higher scores representing a greater degree of disease severity (scale: 0 to 30). Eligible participants were randomized to receive intravenously administered Pasatru 10 mg/kg, Pasatru 3 mg/kg, or placebo once every four weeks for 56 weeks. Following this, participants could elect to then continue their originally assigned treatment in a double-blind extension phase for at least 84 weeks or discontinue treatment and enter an observation-only arm. 

During the treatment period, efficacy was evaluated through whole body CT scans for HO lesions, physician and patient assessment of flare-ups, utilization of CAJIS to rate joint functionality, and observances of change in disease severity. Safety assessment includes reports of adverse events, measurement of vital signs, physical examination, and coagulation testing. 

A Phase 3 trial of Pasatru in adolescents and children with FOP, OPTIMA 2, is planned to begin later this year. For more information, visit the Regeneron clinical trials website, contact [email protected] or call +1 844-734-6643. 

About Pasatru
Regeneron has been engaged in FOP research for decades and helped to provide fundamental insights into the biology and natural history of the disease. Regeneron scientists discovered that Activin A plays a key role in FOP by driving HO, the main pathology of FOP. Pasatru is a VelocImmune-derived, fully human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. 

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PASATRU?

PASATRU can cause serious side effects, including:

Harm to your unborn baby including serious birth defects if taken during pregnancy. Females who are pregnant must not take PASATRU. Females who can become pregnant: Your healthcare provider will ask you to take a pregnancy test to verify that you are not pregnant before starting treatment with PASATRU.Use effective birth control (contraception) during treatment with PASATRU and for 6 months after the last dose of PASATRU. Talk to your healthcare provider about birth control methods that may be right for you.If you become pregnant or think you may be pregnant during treatment with PASATRU, stop taking PASATRU immediately and call your healthcare provider right away. Infections of the skin and tissue under the skin requiring treatment or hospitalization, such as infected lumps (abscesses) and bacterial skin infections (cellulitis), may happen while you are taking PASATRU. Call your healthcare provider right away if you have signs or symptoms of skin infection, such as: rednessskin feels warm to the touchswelling pain or tendernessfeverfeeling generally unwell Nosebleeds (epistaxis) including serious nosebleeds that require medical care, can happen while taking PASATRU. Tell your healthcare provider right away if you have a nosebleed that: is severe or heavydoes not stop with basic first-aid measures, such as pinching your nose with continuous firm pressurelasts more than 20 minutes Do not receive PASATRU if you are pregnant.

Before you receive PASATRU, tell your healthcare provider about all your medical conditions, including if you:

are breastfeeding. It is not known whether PASATRU passes into your breastmilk. Breastfeeding is not recommended during treatment with PASATRU and for 6 months after the last dose of PASATRU. Talk to your healthcare provider about the best way to feed your baby during this time.are concerned about male fertility. PASATRU may affect your ability to father a child. Talk to your healthcare provider if this is concern for you. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of PASATRU include:

infected lumps (abscess)acneincreased hair growth hair loss of eyebrows or lashes (madarosis)
mouth sores (oral ulcers)nosebleeds (epistaxis) These are not all of the possible side effects of PASATRU. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is PASATRU?

PASATRU™ (garetosmab-grts) is a prescription medicine used to reduce the formation of new abnormal bone growth outside of the skeleton (heterotopic ossification) and flare-ups in adults with fibrodysplasia ossificans progressiva (FOP).

It is not known if PASATRU is safe and effective in children.

Please click here for full Prescribing Information, including Medication Guide.

About Regeneron’s VelocImmune Technology 
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce fully optimized human antibodies. When Regeneron's Co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn), Veopoz® (pozelimab-bbfg) and Pasatru™ (garetosmab-grts). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. A total of 11 antibody and bispecific products have been approved or authorized worldwide that were invented or derived using VelocImmune technologies.

About Regeneron 
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.  

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. 

Forward-Looking Statements and Use of Digital Media 

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Pasatru™ (garetosmab-grts) to reduce the formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products (such as Pasatru) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Pasatru) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Posted by Defense World Staff on Aug 1st, 2026

Bank of America Corp DE raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,189,584 shares of the biopharmaceutical company’s stock after buying an additional 32,158 shares during the quarter. Bank of America Corp DE owned approximately 1.13% of Regeneron Pharmaceuticals worth $919,120,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $1,012,296,000. Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the period. Nuveen LLC raised its position in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares during the period. Wellington Management Group LLP lifted its stake in shares of Regeneron Pharmaceuticals by 8,620.0% during the fourth quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after purchasing an additional 656,845 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 528.7% during the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after purchasing an additional 606,612 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Q2 results substantially exceeded expectations. Regeneron reported non-GAAP EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue rose 16.7% year over year. Growth was led by record Dupixent sales, which increased 38%, and U.S. EYLEA HD sales, which jumped 52% to $596 million. Regeneron Q2 2026 Results Positive Sentiment: Several analysts raised their price targets after the report. Cantor Fitzgerald lifted its target to $795 and maintained an overweight rating, while Truist raised its target to $772 and reiterated buy. These targets imply additional upside based on the referenced current price. Analyst Price Target Updates Neutral Sentiment: Analyst sentiment remains mixed. Morgan Stanley raised its target to $758 and RBC to $737, but both maintained equal-weight or sector-perform ratings. Wells Fargo also raised its target to $750 while keeping an equal-weight rating, suggesting limited conviction despite the earnings beat. Analyst Price Target Updates Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield is modest and is unlikely to be a major stock catalyst. Negative Sentiment: Multiple law firms publicized a securities class action against Regeneron and its executives. The litigation alleges investors were misled about the protocol and prospects of the Phase 3 fianlimab-Libtayo melanoma trial, which ultimately failed and was associated with an approximately $11 billion market-cap loss. The September 14, 2026 lead-plaintiff deadline and continuing legal notices could pressure sentiment and create potential financial and reputational risks. Regeneron Securities Class Action Regeneron Pharmaceuticals Stock Up 3.3% REGN stock opened at $762.63 on Friday. The company has a quick ratio of 2.96, a current ratio of 4.29 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The firm’s 50-day simple moving average is $643.13 and its 200 day simple moving average is $711.70. The stock has a market cap of $80.63 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 29.50 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the previous year, the business earned $12.81 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 2.06 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Wall Street Analysts Forecast Growth Several research firms recently issued reports on REGN. Canaccord Genuity Group dropped their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research report on Friday. Leerink Partners restated a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $794.83.

Read Our Latest Analysis on REGN

Insider Activity In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile (Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Further Reading Five stocks we like better than Regeneron Pharmaceuticals Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of America Corp DE Acquires 392,210 Shares of Southern Company (The) $SO

NEXT HEADLINE »Bank of America Corp DE Sells 823,167 Shares of Altria Group, Inc. $MO

Regeneron (REGN - Free Report) came out with quarterly earnings of $14.29 per share, beating the Zacks Consensus Estimate of $10 per share. This compares to earnings of $12.89 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +42.90%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $8.52 per share when it actually produced earnings of $9.47, delivering a surprise of +11.15%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Regeneron, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.29 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 11.74%. This compares to year-ago revenues of $3.68 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Regeneron shares have lost about 9.9% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Regeneron?While Regeneron has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Regeneron was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $12.58 on $4.1 billion in revenues for the coming quarter and $45.50 on $15.75 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Geron (GERN - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.

This drugmaker is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Geron's revenues are expected to be $55.01 million, up 12.2% from the year-ago quarter.

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing

FDA accepted NDA under Priority Review with a target action date in November 2026; European Commission decision anticipated in the second half of 2027

TARRYTOWN, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the regulatory applications for cemdisiran to treat adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA will review the New Drug Application (NDA) under Priority Review with a target action date in November 2026, following use of a Priority Review Voucher. A decision from the European Commission is anticipated in the second half of 2027.

The submissions are supported by data from the Phase 3 NIMBLE trial evaluating cemdisiran, dosed subcutaneously every 12 weeks, in adults with symptomatic gMG who may be receiving standard of care immunosuppressants based on the investigator’s discretion. Full data from NIMBLE, which is one of the largest global, interventional gMG trials conducted to date, were simultaneously published in The Lancet and presented at the American Academy of Neurology (AAN) Annual Meeting in April 2026. A regulatory filing in Japan is also planned for early 2027.

MG is a rare and chronic autoimmune disease where abnormal anti-AChR antibodies activate the complement system including C5, disrupting communication between nerves and muscles that results in debilitating and potentially life-threatening muscle weakness. Worldwide, an estimated 150 to 200 out of every million people have MG. In the U.S., the disease impacts approximately 85,000 people. Initial manifestations are usually ocular, but approximately 85% of MG patients experience progression to additional disease manifestations, which is then categorized as generalized MG. For these patients, the disease affects muscles throughout the body, resulting in extreme fatigue and difficulties with facial expression, speech, swallowing and mobility. For patients living with gMG, many continue to experience challenges with disease management including treatments that only address symptoms, long-term burden of immunosuppressants, lack of responsiveness as well as waning effectiveness, which can all affect their quality of life.

The safety and efficacy of cemdisiran, as well as its potential use for the treatment of gMG, are investigational and have not been fully evaluated or approved by any regulatory authority.

Regeneron is solely responsible for the development, manufacturing, and commercialization of cemdisiran as a monotherapy and in combination with C5 antibodies through a worldwide licensing agreement with Alnylam.

About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies.

Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes REGEN-COV® (casirivimab and imdevimab), Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab).

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation cemdisiran (an investigational siRNA therapeutic targeting C5); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including cemdisiran for the treatment of adults with generalized myasthenia gravis in the United States and/or European Union as discussed in this press release as well as cemdisiran as a monotherapy or in combination with pozelimab (a C5 antibody) for the treatment of other complement-mediated disorders (including paroxysmal nocturnal hemoglobinuria and/or geographic atrophy secondary to age-related macular degeneration); uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as cemdisiran and pozelimab); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as cemdisiran and pozelimab) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended March 31, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).